View All Spotlights
DECLARE - Clinical Trial Spotlight
Stephen Wiviott, MD: Changes in the Treatment of Type 2 Diabetes
Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.
Stephen Wiviott, MD: Strengths and Limitations of the DECLARE-TIMI 58 Trial
Strengths of the DECLARE-TIMI 58 trial included a large primary prevention population, while the nature of the study meant that adherence was likely higher than it would be in a standard setting.
Dapagliflozin Reduces Heart Failure in Primary Prevention Population
The study showed noninferiority with relation to major adverse cardiovascular events and a reduction of heart failure, though no difference in cardiovascular death compared to placebo. There appear to be renal benefits to dapagliflozin as well.
Top 10 Painkillers in the US
Linagliptin Non-inferior to Glimepiride on Cardiovascular Safety
What Should I Do With This Abnormal ALT?
When to Suspect Diarrhea is Symptom of a Clostridium Difficile
Novel Method Clears Hepatitis C from Donor Lungs
Affordable Care Act
PHYSICIAN'S MONEY DIGEST >
MD Magazine Resources
Terms & Conditions
Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.